Lisa R C Saud1, Aline L Chagas1, Claudia Maccali1, Paulo V A Pinto2, Natally Horvat3, Regiane S S M Alencar1, Claudia M Tani1, Edson Abdala4, Flair J Carrilho1. 1. São Paulo Clínicas Liver Cancer Group, Instituto do Cancer do Estado de São Paulo, Division of Clinical Gastroenterology and Hepatology, Hospital das Clínicas, Department of Gastroenterology, University of São Paulo School of Medicine. 2. São Paulo Clínicas Liver Cancer Group, Hospital das Clínicas, Department of Radiology, University of São Paulo School of Medicine. 3. Radiology Department, Memorial Sloan Kettering Cancer Center, New York. 4. Instituto do Cancer do Estado de São Paulo, Hospital das Clínicas, Infectious Diseases Department, University of São Paulo School of Medicine, São Paulo, Brazil.
Abstract
INTRODUCTION AND OBJECTIVES: Hepatocellular carcinoma (HCC) is the 6th cause of cancer and hepatitis C (HCV) and B (HBV) viruses are the most frequent risk factors for HCC. Patients coinfected with HCV or HBV and HIV present a faster progression to liver fibrosis and higher incidence of HCC. The aim of this study was to evaluate the survival and clinical outcomes of coinfected patients with HCC comparing with non-HIV patients. METHODS: We conducted a retrospective cohort study, including 267 HCC patients with HCV or HBV infection with or without HIV. The primary endpoint was overall survival. A Kaplan-Meier curve was presented to assess survival function. Clinical and radiologic variables, according to HIV status, were compared by logistic regression. RESULTS: Among 267 HCC patients, 25 (9.3%) were HIV-positive. In the coinfected group, patients were younger (49.8 vs 61.2 years, P < 0.001), cirrhosis was less predominant (88 vs 96.7%, P = 0.05), a smaller proportion received HCC treatment (60 vs 86.3%, P = 0.001) and the frequency of portal vein tumoral thrombosis was higher (32 vs 11.1%, P = 0.003). The overall mortality rate was higher in the HIV-positive group (92 vs 74.3%), independently of clinical and tumoral variables. CONCLUSION: Coinfected patients with HCC presented higher mortality, tumor diagnosis in a younger age, less underlying cirrhosis and a higher frequency of tumoral thrombosis. Further studies are warranted to better understand the role of HIV in hepatocarcinogenesis, in order to improve the management of those patients, particularly regarding screening programs.
INTRODUCTION AND OBJECTIVES: Hepatocellular carcinoma (HCC) is the 6th cause of cancer and hepatitis C (HCV) and B (HBV) viruses are the most frequent risk factors for HCC. Patients coinfected with HCV or HBV and HIV present a faster progression to liver fibrosis and higher incidence of HCC. The aim of this study was to evaluate the survival and clinical outcomes of coinfected patients with HCC comparing with non-HIV patients. METHODS: We conducted a retrospective cohort study, including 267 HCC patients with HCV or HBV infection with or without HIV. The primary endpoint was overall survival. A Kaplan-Meier curve was presented to assess survival function. Clinical and radiologic variables, according to HIV status, were compared by logistic regression. RESULTS: Among 267 HCC patients, 25 (9.3%) were HIV-positive. In the coinfected group, patients were younger (49.8 vs 61.2 years, P < 0.001), cirrhosis was less predominant (88 vs 96.7%, P = 0.05), a smaller proportion received HCC treatment (60 vs 86.3%, P = 0.001) and the frequency of portal vein tumoral thrombosis was higher (32 vs 11.1%, P = 0.003). The overall mortality rate was higher in the HIV-positive group (92 vs 74.3%), independently of clinical and tumoral variables. CONCLUSION: Coinfected patients with HCC presented higher mortality, tumor diagnosis in a younger age, less underlying cirrhosis and a higher frequency of tumoral thrombosis. Further studies are warranted to better understand the role of HIV in hepatocarcinogenesis, in order to improve the management of those patients, particularly regarding screening programs.
Authors: Deborah Konopnicki; Amanda Mocroft; S de Wit; Francisco Antunes; Bruno Ledergerber; Christine Katlama; K Zilmer; Stefano Vella; Ole Kirk; Jens D Lundgren Journal: AIDS Date: 2005-03-24 Impact factor: 4.177
Authors: Jessie Torgersen; Michael J Kallan; Dena M Carbonari; Lesley S Park; Rajni L Mehta; Kathryn D'Addeo; Janet P Tate; Joseph K Lim; Matthew Bidwell Goetz; Maria C Rodriguez-Barradas; Cynthia L Gibert; Norbert Bräu; Sheldon T Brown; Jason A Roy; Tamar H Taddei; Amy C Justice; Vincent Lo Re Journal: J Natl Cancer Inst Date: 2020-07-01 Impact factor: 13.506
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: Massimo Puoti; Raffaele Bruno; Vincent Soriano; Francesco Donato; Giovanni Battista Gaeta; Gian Paolo Quinzan; Davide Precone; Umberto Gelatti; Victor Asensi; Emanuela Vaccher Journal: AIDS Date: 2004-11-19 Impact factor: 4.177
Authors: Norbert Bräu; Rena K Fox; Peiying Xiao; Kristen Marks; Zeenat Naqvi; Lynn E Taylor; Anita Trikha; Morris Sherman; Mark S Sulkowski; Douglas T Dieterich; Michael O Rigsby; Teresa L Wright; Maria D Hernandez; Mamta K Jain; Gajendra K Khatri; Richard K Sterling; Maurizio Bonacini; Catherine A Martyn; Ayse Aytaman; Josep M Llovet; Sheldon T Brown; Edmund J Bini Journal: J Hepatol Date: 2007-07-19 Impact factor: 25.083
Authors: Nicolás Merchante; Esperanza Merino; José López-Aldeguer; Francisco Jover; Marcial Delgado-Fernández; Maria José Galindo; Enrique Ortega; Antonio Rivero; Carlos Mínguez; Alberto Romero-Palacios; Sergio Padilla; Manuel Márquez-Solero; Concepción Amador; Maria José Ríos-Villegas; Francisco Téllez; Joaquín Portilla; Juan A Pineda Journal: Clin Infect Dis Date: 2012-09-05 Impact factor: 9.079